FHTX — Foghorn Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1822462 ·
Last close
$4.53
Market Cap
$265.97M
52W High
$6.57
52W Low
$3.54
ADV30
340,417
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 3,267,000 | — | -21,573,000 | -19,875,000 | 222,167,000 | 87,663,000 | 298,575,000 |
| Dec 2025 | 9,247,000 | — | -19,596,000 | -21,664,000 | 198,103,000 | 80,876,000 | 306,603,000 |
| Sep 2025 | 8,153,000 | — | -18,501,000 | -15,849,000 | 204,962,000 | 89,334,000 | 294,620,000 |
| Jun 2025 | 7,557,000 | — | -21,097,000 | -17,936,000 | 226,236,000 | 72,572,000 | 302,895,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-86,099,000
Investing CF
$112,040,000
Financing CF
$1,023,000
CapEx
$-838,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.14
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-632,467,000
Inventory
—
Receivables
—
ST Investments
$78,018,000
EBIT TTM
$-82,107,000
Pretax Income TTM
$-74,283,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$28,224,000
EBITDA
$-78,024,000
Free Cash Flow
$-36,926,376
Enterprise Value
$124,337,064
Total Cash
$183,631,008
Total Debt
$41,994,000
Shares Out
58,713,922
Trailing EPS
$-1.17
Book Value
$-1.30
ROE
—
ROA
-21.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 30,909,000 | -82,107,000 | -74,283,000 | 198,103,000 | 306,603,000 | — | -86,099,000 |
| Dec 2024 | 22,602,000 | -100,285,000 | -86,620,000 | 283,982,000 | 329,510,000 | — | -100,406,000 |
| Dec 2023 | 34,155,000 | -107,906,000 | -98,426,000 | 285,916,000 | 363,106,000 | — | -118,106,000 |
| Dec 2022 | 19,228,000 | -117,137,000 | -108,882,000 | 404,883,000 | 404,771,000 | — | 193,612,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.10
Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $4.53 · call volume: 24 · put volume: 1Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SLGL | Sol-Gel Technologies Ltd. | $266.92M | $82.25 | — |
| IMRX | Immuneering Corp | $267.20M | $4.13 | — |
| TRDA | Entrada Therapeutics, Inc. | $263.59M | $6.79 | — |
| NWBO | NORTHWEST BIOTHERAPEUTICS INC | $262.93M | $0.16 | — |
| ALXO | ALX ONCOLOGY HOLDINGS INC | $261.05M | $1.94 | — |
News headlines (Yahoo Finance, 1h cache)
Acadia Healthcare (ACHC) Surpasses Q2 Earnings and Revenue Estimates
2026-07-28 22:00 · Yahoo
Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains?
2026-07-03 11:42 · Yahoo
Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
2026-06-05 11:00 · Yahoo
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May
2026-05-12 11:00 · Yahoo
The Foghorn Therapeutics Inc. (NASDAQ:FHTX) First-Quarter Results Are Out And Analysts Have Published New Forecasts
2026-05-11 15:02 · Yahoo
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
2026-05-07 14:00 · Yahoo
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates
2026-05-07 12:50 · Yahoo
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
2026-05-07 11:00 · Yahoo
Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top Estimates
2026-05-06 21:25 · Yahoo
Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
2026-05-06 14:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.